The desired treatment approach in acromegaly patients should take all the individual traits of the disease into consideration, such as: GH and IGF-1 levels, tumour size, acromegaly symptoms, comorbidities, costs, QoL and patient preferences. This evidence concerns the gene IGF1 and neoplasm.